BMI and lymph node ratio may predict clinical outcomes of gastric cancer

Future Oncology

Volumn 10, Issue 2, 2014, Pages 249-255

  Lianos, Georgios D ^a,b   Bali, Christina D ^a,b   Glantzounis, Georgios K ^a,b   Katsios, Christos ^a,b   Roukos, Dimitrios H ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

BMI; complications; gastric cancer; lymph node ratio; prognostic factors; survival

Indexed keywords

AGED; AGED, 80 AND OVER; BODY MASS INDEX; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84893849180     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.188     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay G, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Scartozzi M, Pistelli M, Bittoni A et al. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr. Oncol. Rep. 12(3), 175-85 (2010).
3. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum. Genet. 126(5), 615-628 (2009).
4. Yoon SS, Yang HK. Lymphadenectomy for gastric adenocarcinoma: should west meet east? Oncologist 14(9), 871-882 (2009).
5. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 374(9688), 477-490 (2009).
6. Misleh JG, Santoro P, Strasser JF, Bennett JJ. Multidisciplinary management of gastric cancer. Surg. Oncol. Clin. N. Am. 22(2), 247-264 (2013).
7. Yasui W. Future perspectives of gastric cancer treatment: from bench to bedside. Pathobiology 78(6), 293-294 (2011).
8. Lee SS, Ryu SW, Kim IH, Sohn SS. Impact of gender and body mass index on surgical outcomes following gastrectomy: an Asia-Pacific perspective. Chin. Med. J. (Engl.) 125(1), 67-71 (2012).
9. Medina-Franco H, Cabrera-Mendoza F, Almaguer-Rosales S, Guillén F, Suárez-Bobadilla YL, Sánchez-Ramón A. Lymph node ratio as a predictor of survival in gastric carcinoma. Am. Surg. 79(3), 284-289 (2013).
10. Seo SH, Hur H, An CW et al. Operative risk factors in gastric cancer surgery for elderly patients. J. Gastric Cancer 11(2), 116-121 (2011).
11. Lamb P, Sivashanmugam T, White M, Irving M, Wayman J, Raimes S. Gastric cancer surgery-a balance of risk and radicality. Ann. R. Coll. Surg. Engl. 90(3), 235-242 (2008). (Pubitemid 351593724)
12. Saka M, Morita S, Fukagawa T, Katai H. Present and future status of gastric cancer surgery. Jpn J. Clin. Oncol. 41(3), 307-313 (2011).
13. Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: east vs. west. J. Gastric Cancer 12(2), 55-62 (2012).
14. Kitadai Y. Angiogenesis and lymphangiogenesis of gastric cancer. J. Oncol. 2010, 468725 (2010).
15. Nobili S, Bruno L, Landini I et al. Genomic and genetic alterations influence the progression of gastric cancer. World J. Gastroenterol. 17(3), 290-299 (2011).
16. Takayama S, Wakasugi T, Funahashi H, Takeyama H. Strategies for gastric cancer in the modern era. World J. Gastrointest. Oncol. 2(9), 335-341 (2010).
17. Asoglu O, Karanlik H, Parlak M et al. Metastatic lymph node ratio is an independent prognostic factor in gastric cancer. Hepatogastroenterology 56(91-92), 908-913 (2009).
18. Feng J, Wu YF, Xu HM, Wang SB, Chen JQ. Prognostic significance of the metastatic lymph node ratio in T3 gastric cancer patients undergoing total gastrectomy. Asian Pac. J. Cancer Prev. 12(12), 3289-3292 (2011).
19. Latengbaolide A, Lin D, Li Y et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am. J. Clin. Oncol. 36(4), 325-330 (2012).
20. Ojima T, Iwahashi M, Nakamori M et al. Influence of overweight on patients with gastric cancer after undergoing curative gastrectomy: an analysis of 689 consecutive cases managed by a single center. Arch. Surg. 144(4), 351-358 (2009).
21. Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamaguchi T, Nakajima T. Better 5-year survival rate following curative gastrectomy in overweight patients. Ann. Surg. Oncol. 169(12), 3245-3251 (2009).
22. Kulig J, Sierzega M, Kolodziejczyk P et al. Implications of overweight in gastric cancer: a multicenter study in a western patient population. Eur. J. Surg. Oncol. 36(10), 969-976 (2010).
23. Nobuoka D, Gotohda N, Kato Y, Takahashi S, Konishi M, Kinoshita T. Influence of excess body weight on the surgical outcomes of total gastrectomy. Surg. Today 41(7), 928-934 (2011).
24. Chen JG, Xia JC, Liang XT et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int. J. Biol. Sci. 7(1), 53-60 (2011).
25. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med. J. 53(2), 248-257 (2012).
26. Bornschein J, Malfertheiner P. Gastric carcinogenesis. Langenbecks Arch. Surg. 396(6), 729-742 (2011).
27. Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch. Arztebl. Int. 108(41), 698-705 (2011).
28. Stamatoyannopoulos JA. What does our genome encode? Genome Res. 22(9), 1602-1611 (2012).
29. Maurano MT, Humbert R, Rynes E et al. Systematic localization of common diseaseassociated variation in regulatory DNA. Science 337(6099), 1190-1195 (2012).
30. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336(6082), 736-739 (2012).
31. Wang H, Maurano MT, Qu H et al. Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res. 22(9), 1680-1688 (2012).
32. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
33. Sanford M. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. Drugs 73(14), 1605-1615 (2013).
34. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56-68 (2011).
35. Wang E. Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Lett. 340(2), 261-269 (2013).
36. Erler JT, Linding R. Network medicine strikes a blow against breast cancer. Cell 149(4), 731-733 (2012).
37. Guo S, Zou J, Wang G. Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des. Devel. Ther. 7, 1259-1271 (2013).